FAPI PET Imaging Superior for Diagnosing Multiple Types of Cancer, with Potential for Targeted Treatment (IMAGE)

Society of Nuclear Medicine and Molecular Imaging

FAPI PET Imaging Superior for Diagnosing Multiple Types of Cancer, with Potential for Targeted Treatment

Caption

TOP: Supplemental Figure 6. A 57-year-old male with stage 1B pancreatic adenocarcinoma (T2N0M0). (A) FAPI maximum-intensity projection (B) fused FAPI PET/CT (C) FAPI PET and (D) accompanying low dose CT along with concomitant (E) FDG maximum-intensity projection (F) fused FDG PET/CT (G) FDG PET and (H) accompanying high dose CT. Arrows point towards primary lesion in the pancreas (FAP SUVmax 25.1, FDG SUVmax 6.2). BOTTOM: Supplemental Figure 7B. Optimization of the specific activities of 111In-FAP6-IP-DOTA in HT29 tumors over time as a function of molar amount of FAP6 conjugate injected while maintaining the dose of radioactivity constant (~10 MBq). Arrows: a = 4T1 tumors; b = liver; c = kidneys.

Credit

TOP: Images created by N Hirmas, R Hamacher, M Sraieb, et al., University Hospital Essen, Essen, Germany. BOTTOM: Images created by Spencer D. Lindeman, Autumn Horner, and Jackson N. Moss, Purdue Institute for Drug Discovery and Purdue Imaging Facility, West Lafayette, IN.

Usage Restrictions

Please give appropriate credit.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.